Skip to main content
All lobbying filings

PHLOW CORPORATION

Lobbying for PHLOW CORPORATION

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Virginia · House · Senate · $400,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 4
 Lobbying activity 3
Budget/Appropriations

FY27 Labor, Health and Human Services, Education, and Related Agencies Appropriations (no bill numbers); FY27 Department of Defense Appropriations (no bill numbers)

Health Issues

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Manufacturing

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem